Sinocare

Sinocare Gross Margin

The Gross Margin of Sinocare (300298.SZ) as of Oct 23, 2026 is 48.74 %. In the previous year, Gross Margin was 54.40 % — a change of -10.41% (lower).

Gross Margin

48.74 %

YoY

-10.41%

Last updated:

Gross Margin of Sinocare is 2025 48.74 % . Gross Margin of Sinocare was 2024 54.40 % . It decreases by -10.41% lower compared to the previous year.

For Sinocare, the gross margin of 48.7% is down versus 58.7% a few years ago.

The Sinocare Gross Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Gross Margin
Date
Gross Margin
Jan 1, 2018
63.66 CNY
Jan 1, 2019
64.71 CNY
Jan 1, 2020
64.53 CNY
Jan 1, 2021
58.69 CNY
Jan 1, 2022
51.96 CNY
Jan 1, 2023
52.96 CNY
Jan 1, 2024
54.40 CNY
Jan 1, 2025
48.74 CNY
The Sinocare Gross Margin history
YEARGross MarginYoY
48.74 %-10.41%
54.40 %+2.72%
52.96 %+1.93%
51.96 %-11.47%
58.69 %-9.04%
64.53 %-0.28%
64.71 %+1.65%
63.66 %-5.68%
67.49 %+5.33%
64.08 %-2.57%
65.76 %-4.55%
68.90 %+10,154.27%
0.67 %-4.13%
0.70 %+0.01%
0.70 %+9.40%
0.64 %-4.70%
0.67 %+47.16%
0.46 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Sinocare Stock analysis

What does Sinocare do? Sinocare, Inc. generates revenue through the development, production, and sale of chronic disease rapid detection products, primarily focusing on blood sugar monitoring systems. The company offers blood sugar testing instruments, related strips, blood sugar testing systems, and mobile blood sugar instruments under its SANNUO brand. These products are sold domestically and internationally, targeting healthcare providers and consumers managing diabetes. Sinocare also provides diabetes management information systems as part of its product portfolio. The SANNUO brand is central to Sinocare's sales strategy, with products distributed across domestic and overseas markets. The company's offerings include micro blood instant blood sugar monitoring systems, which are designed for chronic disease management. Sinocare's revenue streams are derived from direct sales of these medical devices and associated information systems to end-users and healthcare institutions. Sinocare's business model relies on the consistent demand for diabetes management solutions, with its SANNUO-branded products serving both individual consumers and healthcare facilities. The company's product range includes blood sugar testing instruments, strips, and mobile blood sugar instruments, all marketed under the SANNUO label. These products are distributed globally, supporting Sinocare's revenue generation through direct sales channels. Sinocare is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Sinocare stock

Gross Margin of Sinocare is 48.74 % in 2025.

Gross Margin of Sinocare changed from 54.40 % to 48.74 %, representing a -10.41% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Gross Margin Sinocare since 2006 – with annual values, charts, and detailed analysis.

Gross Margin measures the percentage of revenue remaining after COGS. Higher gross margins indicate more efficient production and stronger pricing power.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Gross Margin's Sinocare with sector peers and the industry average to assess whether it is attractive.

To evaluate Gross Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Gross Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Sinocare

All Key Metrics — Sinocare